David Hui1, Angela Xu2, Susan Frisbee-Hume2, Gary Chisholm3, Margarita Morgado2, Suresh Reddy2, Eduardo Bruera2. 1. Department of Palliative Care and Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. Electronic address: dhui@mdanderson.org. 2. Department of Palliative Care and Rehabilitation Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 3. Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Abstract
CONTEXT: Dyspnea is one of the most distressing symptoms in patients with cancer, and often worsens with breakthrough episodes on exertion. We hypothesized that fentanyl given prophylactically may alleviate breakthrough dyspnea. OBJECTIVES: To determine the feasibility of conducting a randomized trial of subcutaneous fentanyl in patients with cancer, and examine the effects of fentanyl on dyspnea, walk distance, vital signs, and adverse events. METHODS: In this double-blind, randomized, controlled trial, we asked ambulatory patients with breakthrough dyspnea to perform a baseline six minute walk test (6MWT), and then assigned them to either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. We documented the change in dyspnea Numeric Rating Scale (NRS) score, walk distance, vital signs, and adverse events between the first and second 6MWT. RESULTS: A total of 20 patients were enrolled (1:1 ratio) without attrition. Comparison between baseline and second walk showed that fentanyl was associated with significant improvements in dyspnea NRS score at the end of the 6MWT (mean [95% CI] -1.8 [-3.2, -0.4]), dyspnea NRS score at rest of 15 minutes after drug administration (-0.9 [-1.8, -0.04]), Borg Scale fatigue score at the end of the 6MWT (-1.3 [-2.4, -0.2]), 6MWT distance (+37.2m [5.8, 68.6]), and respiratory rate (-2.4 [-4.5, -0.3]). Nonstatistically significant improvements also were observed in the placebo arm, with no difference between the two study arms. No significant adverse effects were observed. CONCLUSION:Prophylactic fentanyl was safe and improved dyspnea, fatigue, walk distance, and respiratory rate. We also observed a large placebo effect. Our results justify larger randomized controlled trials with higher fentanyl doses (clinicaltrials.gov registration: NCT01515566).
RCT Entities:
CONTEXT: Dyspnea is one of the most distressing symptoms in patients with cancer, and often worsens with breakthrough episodes on exertion. We hypothesized that fentanyl given prophylactically may alleviate breakthrough dyspnea. OBJECTIVES: To determine the feasibility of conducting a randomized trial of subcutaneous fentanyl in patients with cancer, and examine the effects of fentanyl on dyspnea, walk distance, vital signs, and adverse events. METHODS: In this double-blind, randomized, controlled trial, we asked ambulatory patients with breakthrough dyspnea to perform a baseline six minute walk test (6MWT), and then assigned them to either subcutaneous fentanyl or placebo 15 minutes before a second 6MWT. We documented the change in dyspnea Numeric Rating Scale (NRS) score, walk distance, vital signs, and adverse events between the first and second 6MWT. RESULTS: A total of 20 patients were enrolled (1:1 ratio) without attrition. Comparison between baseline and second walk showed that fentanyl was associated with significant improvements in dyspnea NRS score at the end of the 6MWT (mean [95% CI] -1.8 [-3.2, -0.4]), dyspnea NRS score at rest of 15 minutes after drug administration (-0.9 [-1.8, -0.04]), Borg Scale fatigue score at the end of the 6MWT (-1.3 [-2.4, -0.2]), 6MWT distance (+37.2m [5.8, 68.6]), and respiratory rate (-2.4 [-4.5, -0.3]). Nonstatistically significant improvements also were observed in the placebo arm, with no difference between the two study arms. No significant adverse effects were observed. CONCLUSION: Prophylactic fentanyl was safe and improved dyspnea, fatigue, walk distance, and respiratory rate. We also observed a large placebo effect. Our results justify larger randomized controlled trials with higher fentanyl doses (clinicaltrials.gov registration: NCT01515566).
Authors: Alberto A Gauna; Sheila K Kang; Mary Lawhon Triano; Erica Rachel Swatko; Vincent Jay Vanston Journal: J Palliat Med Date: 2008-05 Impact factor: 2.947
Authors: Miguel Angel Benítez-Rosario; Inmaculada Rosa-González; Enrique González-Dávila; Emilio Sanz Journal: Support Care Cancer Date: 2018-06-18 Impact factor: 3.603
Authors: David Hui; Kelly Kilgore; Susan Frisbee-Hume; Minjeong Park; Anne Tsao; Marvin Delgado Guay; Charles Lu; William William; Katherine Pisters; George Eapen; Frank Fossella; Sapna Amin; Eduardo Bruera Journal: J Pain Symptom Manage Date: 2016-06-18 Impact factor: 3.612
Authors: Luis Cabezón-Gutiérrez; Parham Khosravi-Shahi; Sara Custodio-Cabello; Francisco Muñiz-González; Maria Del Puerto Cano-Aguirre; Soledad Alonso-Viteri Journal: Support Care Cancer Date: 2016-06-22 Impact factor: 3.603
Authors: D Tomlinson; P D Robinson; S Oberoi; D Cataudella; N Culos-Reed; H Davis; N Duong; F Gibson; M Götte; P Hinds; S L Nijhof; P van der Torre; S Cabral; L L Dupuis; L Sung Journal: Curr Oncol Date: 2018-04-30 Impact factor: 3.677
Authors: Josephine L Feliciano; Julie M Waldfogel; Ritu Sharma; Allen Zhang; Arjun Gupta; Ramy Sedhom; Jeff Day; Eric B Bass; Sydney M Dy Journal: JAMA Netw Open Date: 2021-02-01